Cytodyn Distribution Agreement

“This pre-reading distribution agreement for CytoDyn`s COVID-19 clinical trials continues to underscore cytoDyn`s commitment to making leronlimab immediately available to patients based on the success of ongoing clinical trials,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “We are particularly pleased with the partnership with a company with proven expertise, unprecedented business reach and American Regent`s excellent reputation.” SAN DIEGO, May 5, 2020 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical development and manufacturing services, is pleased to announce that it has entered into a manufacturing service agreement with CytoDyn Inc., a late-stage biotechnology company, for the supply of the new leronlimab trial drug (PRO 140), currently used in clinical trial protocols for patients with moderate moderate and severely ill patients. “We look forward to working with Samsung BioLogics, one of the best CMO companies in the world. As the company has always demonstrated an extremely high level of quality assurance, performance and profitability, we expect to be able to market our new drug quickly after an expected marketing approval,” said Nader Pourhassan, Ph.D. President, CEO and Ceo of CytoDyn. “It is important for our shareholders to realize that our partnership with Samsung is the first step towards validating what we have accomplished and the future potential for leronlimab,” continues Dr. Pourhassan. “One of our biggest strategic challenges, with the potential to sell leronlimab in monotherapy (provided we get approval) was to ensure that we had sufficient production capacity for large-scale basic biologics to meet expected demand, and our Samsung agreement now successfully meets this long-term strategic requirement,” concludes Dr. Pourhassan. INCHEON, South Korea, May 30, 2019 /PRNewswire/ — CytoDyn Inc., a late-stage biotechnology company, which is developing leronlimab (PRO 140), a CCR5 antagonist with the potential of several therapeutic indications and Samsung BioLogics met at Samsung BioLogics Songdo headquarters for an official signing and signing of the production agreement with Samsung BioLogics, previously announced on April 2, 2019.

Comments are closed.

Powered by WordPress. Designed by Woo Themes